Associate Program Director of the Hematology Medical Oncology Fellowship Program
Education and Training
Cornell University, Ithaca, NY: B.S., Human Biology, Health & Society
State University of New York Upstate Medical University, Syracuse, NY: M.D.
University of Maryland Medical Center, Baltimore, MD: Internal Medicine Residency
University of Maryland Medical Center, Baltimore, MD: Hematology/Oncology Fellowship
Katherine Scilla, MD, FACP is an Assistant Professor of Medicine at the University of Maryland School of Medicine and a medical oncologist at the University of Maryland Greenebaum Comprehensive Cancer Center. She has expertise in treating thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, malignant pleural mesothelioma and thymic cancers.
Dr. Scilla earned her undergraduate degree from Cornell University, majoring in Human Biology, Health & Society. She received her medical degree from State University of New York Upstate Medical University. She completed both her internal medicine residency training and hematology/oncology fellowship training at the University of Maryland Medical Center. She joined the faculty of the University of Maryland in 2017.
Thoracic Oncology, Lung cancer
Lam VK, Bentzen SM, Mohindra P, Nichols EM, Bhooshan N, Vyfhuis M, Scilla KA, Feigenberg SJ, Edelman MJ, Feliciano JL. Obesity Is Associated With Long-Term Improved Survival in Definitively Treated Locally Advanced Non-Small Cell Lung Cancer (NSCLC). Lung Cancer. 2017 Feb;104:52-57.
Scilla KA, Bentzen SM, Lam VK, Mohindra P, Nichols EM, Vyfhuis MA, Bhooshan N, Feigenberg SJ, Edelman MJ, Feliciano JL. Neutrophil-lymphocyte ratio (NLR) is a prognostic marker in patients with locally advanced (Stage IIIA & IIIB) non-small cell lung cancer treated with combined modality therapy. Oncologist. 2017 Jun;22(6):737-742.
Scilla KA, Zandberg DP, Bentzen SM, Mainor CB, Heath J, Ioffe OB, Cellini AL, Edelman MJ, Riedel DJ, Feliciano JL. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection. Lung Cancer. 2018 Sep;123:87-90.
Scilla KA, Rolfo C. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future. Curr Treat Options Oncol. 2019 Jun 15;20(7):61.
McCusker MG, Scilla KA, Simone CB 2nd, Sachdeva A, Miller KD, Burke AP, Rolfo C. Proton Beam Therapy and Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma. J Thorac Oncol. 2019 Sep;14(9):e185-e187.
Scilla KA, Russo A, Rolfo C. Immunotherapy use in patients with HIV and non-small-cell lung cancer: Current data. J Immunother Precis Oncol 2019;2:55-8.
Rice SR, Vyfhuis MAL, Scilla KA, Burrows WM, Bhooshan N, Suntharalingam M, Edelman MJ, Feliciano J, Badiyan SN, Simone CB 2nd, Feigenberg SJ, Mohindra P. Insurance status is an independent predictor of overall survival in patients with stage III non-small cell lung cancer treated with curative intent. Clin Lung Cancer. 2020 May;21(3):e130-e141.